Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic Sclerosis

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1399-1406

  Birgani, Shadab Allipour ^a   Mailänder, Marion ^a   Wasle, Ines ^a   Dietrich, Hermann ^a   Gruber, Johann ^a   Distler, Oliver ^b   Sgonc, Roswitha ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; TRANSCRIPTION FACTOR TAL1; VASCULOTROPIN 121; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHICKEN; CLINICAL ASSESSMENT; CONTROLLED STUDY; IMMUNOFLUORESCENCE TEST; MICROVASCULATURE; MONOTHERAPY; NECK INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SKIN DEFECT; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; UNIVERSITY OF CALIFORNIA AT DAVIS 206; UPREGULATION; ANIMAL; COMPLICATION; DISEASE MODEL; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SKIN ULCER;

ANIMALS; CHICKENS; DISEASE MODELS, ANIMAL; FIBRIN; NEOVASCULARIZATION, PATHOLOGIC; SCLERODERMA, SYSTEMIC; SKIN ULCER; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84941662366     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207548     Document Type: Article

References (44)

1. Gabrielli A, Avvedimento EV, Krieg T. Mechanisms of disease: scleroderma. New Engl J Med 2009;360:1989-2003.
2. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Ann Rev Pathol 2011;6:509-37.
3. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
4. Wick G, Andersson L, Hala K, et al. Avian models with spontaneous autoimmune diseases. Adv Immunol 2006;92:71-117.
5. Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol 1999;120:169-76.
6. Kahaleh MB. Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 2004;16:718-22.
7. Beyer C, Schett G, Gay S, et al. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Thr 2009;11:220.
8. Trojanowska M. Cellular and molecular aspects of vascular dysfunctions in systemic sclerosis. Nat Rev Rheumatol 2010;6:453-60.
9. Liakouli V, Cipriani P, Marrelli A, et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011;10:590-4.
10. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011;27:563-84.
11. Distler O, Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
12. Riccieri V, Stefanantoni K, Vasile M, et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 2011;29:S46- S52.
13. Avouac J, Vallucci M, Smith V, et al. Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res Ther 2013;15:R55.
14. Distler O, Distler JHW, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
15. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000;6:1102-3.
16. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Acad Sci USA 1995;92:7657-61.
17. Sulli A, Secchi ME, Pizzorni C, et al. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-7.
18. Manetti M, Guiducci S, Romano E, et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis 2013;72:1425-7.
19. Bielecki M, Kowal K, Lapinska A, et al. Peripheral blood mononuclear cells from patients with systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease. Adv Med Sci 2011;56:255-63.
20. Vale PR, Isner JM, Rosenfield K. Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol 2001;14:511-28.
21. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901.
22. Dor Y, Djonov V, Abramovitch R, et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002;21:1939-47.
23. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26.
24. Eming SA, Hubbell JA. Extracellular matrix in angiogenesis: dynamic structures with translational potential. Exp Dermatol 2011;20:605-13.
25. Zisch AH, Schenk U, Schense JC, et al. Covalently conjugated VEGF-fibrin matrices for endothelialization. J Control Release 2001;72:101-13.
26. Ehrbar M, Djonov VG, Schnell C, et al. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res 2004;94:1124-32.
27. Ecker RC, Steiner GE. Microscopy-based multicolor tissue cytometry at the single-cell level. Cytometry A 2004;59:182-90.
28. Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol 2001;54:343-9.
29. Manetti M, Guiducci S, Romano E, et al. Overexpression of VEGF 165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011;109:e14- e26.
30. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
31. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23.
32. Fan CL, Gao PJ, Gu YJ, et al. Therapeutic angiogenesis by intramuscular injection of fibrin particles into ischaemic hindlimbs. Clin Exp Pharmacol Physiol 2006;33:617-22.
33. Tsopanoglou NE, Maragoudakis ME. Thrombin's central role in angiogenesis and pathophysiological processes. Eur Cytokine Netw 2009;20:171-9.
34. Dardik R, Solomon A, Loscalzo J, et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 2003;23:1472-7.
35. Dardik R, Loscalzo J, Eskaraev R, et al. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005;25:526-32.
36. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011;437:169-83.
37. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998;95:9349-54.
38. Eming SA, Lauer G, Cole M, et al. Increased levels of the soluble variant of the vascular endothelial growth factor receptor VEGFR-1 are associated with a poor prognosis in wound healing. J Invest Dermatol 2004;123:799-802.
39. Edelbauer M, Kshirsagar S, Riedl M, et al. Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis. Pediatr Nephro 2012;27:793-800.
40. Le Roux S, Pepper RJ, Dufay A, et al. Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2012;23:155-64.
41. Mackiewicz Z, Sukura A, Povilenaité D, et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol 2002;20:641-6.
42. Carrai V, Miniati I, Guiducci S, et al. Evidence for reduced angiogenesis in bone marrow in SSc: Immunohistochemistry and multiparametric computerized imaging analysis. Rheumatology 2012;51:1042-8.
43. Kappel A, Schlaeger TM, Flamme I, et al. Role of SCL/Tal-1, GATA, and ets transcription factor binding sites for the regulation of Flk-1 expression during murine vascular development. Blood 2000;96:3078-85.
44. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703.